Recombinant Human CCL26 Protein，His

CCL26, also known as eotaxin-3, is a member of the CC chemokine family, primarily involved in the recruitment of eosinophils and Th2 cells to sites of inflammation, particularly in allergic and asthmatic conditions. Research has highlighted its critical role in various pathophysiological processes, including asthma, atopic dermatitis, and tissue remodeling. The interest in CCL26 recombinant protein has surged due to its potential as a therapeutic target for allergic diseases, where elevated levels are often observed. Furthermore, understanding the precise molecular mechanisms by which CCL26 mediates immune responses and tissue inflammation can provide insights into novel treatment strategies. The recombinant form of CCL26 allows for in-depth studies of its biological activity, receptor interactions, and downstream signaling pathways, facilitating the exploration of its role in immune modulation. By investigating CCL26's structure-function relationships and its interactions with other immune mediators, researchers aim to develop effective interventions that can mitigate the adverse effects of excessive eosinophil recruitment and activation in allergic diseases. This ongoing research not only holds promise for enhancing current therapeutic options but also aims to elucidate the broader implications of chemokines in the regulation of immune responses and the development of targeted therapies for inflammatory conditions.